326 related articles for article (PubMed ID: 23385615)
1. Eosinophilic myeloid neoplasms.
Noel P; Mesa RA
Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
[TBL] [Abstract][Full Text] [Related]
2. Eosinophilic myeloid disorders.
Noel P
Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
[TBL] [Abstract][Full Text] [Related]
3. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
Gotlib J; Cross NC; Gilliland DG
Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
[TBL] [Abstract][Full Text] [Related]
5. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
6. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract][Full Text] [Related]
7. Hypereosinophilic syndrome and proliferative diseases.
Ionescu MA; Wang L; Janin A
Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
[TBL] [Abstract][Full Text] [Related]
8. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
[TBL] [Abstract][Full Text] [Related]
9. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
Gotlib J
Curr Opin Hematol; 2010 Mar; 17(2):117-24. PubMed ID: 20071982
[TBL] [Abstract][Full Text] [Related]
10. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Feb; 14(1):23-31. PubMed ID: 14757533
[TBL] [Abstract][Full Text] [Related]
11. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
Lierman E; Cools J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
[TBL] [Abstract][Full Text] [Related]
12. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
[TBL] [Abstract][Full Text] [Related]
14. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.
Cilloni D; Messa F; Martinelli G; Gottardi E; Arruga F; Defilippi I; Carturan S; Messa E; Fava M; Giugliano E; Rosso V; Catalano R; Merante S; Nicoli P; Rondoni M; Ottaviani E; Soverini S; Tiribelli M; Pane F; Baccarani M; Saglio G
Leukemia; 2007 Jul; 21(7):1442-50. PubMed ID: 17508006
[TBL] [Abstract][Full Text] [Related]
15. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
16. Updates on eosinophilic disorders.
Tzankov A; Reichard KK; Hasserjian RP; Arber DA; Orazi A; Wang SA
Virchows Arch; 2023 Jan; 482(1):85-97. PubMed ID: 36068374
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative hypereosinophilic syndrome presenting as cardiac failure and response to imatinib.
Desai N; Morkhandikar S; Sahay R; Jijina F; Patil P
Am J Ther; 2014; 21(2):e35-7. PubMed ID: 24603276
[TBL] [Abstract][Full Text] [Related]
18. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
Helbig G; Klion AD
Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
[TBL] [Abstract][Full Text] [Related]
20. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1.
Vega F; Medeiros LJ; Bueso-Ramos CE; Arboleda P; Miranda RN
Am J Clin Pathol; 2015 Sep; 144(3):377-92. PubMed ID: 26276769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
